MAB1953
Anti-Integrin αV Antibody, clone P3G8
clone P3G8, Chemicon®, from mouse
Synonym(s):
CD51
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
P3G8, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
ELISA: suitable
flow cytometry: suitable
immunocytochemistry: suitable
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... ITGAV(3685)
Specificity
Reacts with human alphaV integrin subunit and with all alphaV-containing integrin receptors.
Immunogen
UCLA P3 lung carcinoma cells
Application
Anti-Integrin αV Antibody, clone P3G8 is an antibody against Integrin αV for use in ELISA, FC, IP, IC, IH.
Immunohistochemistry: 1:1,000. For use on acetone or paraformaldehyde fixed tissue
Immunocytochemistry: 1:1,000. Will react with some lymphoid cell lines (B cells), many carcinoma and melanoma cell lines and osteosarcomas.
Flow cytometry
Immunoprecipitation
FACS
EIA
Optimal working dilutions must be determined by end user.
Immunocytochemistry: 1:1,000. Will react with some lymphoid cell lines (B cells), many carcinoma and melanoma cell lines and osteosarcomas.
Flow cytometry
Immunoprecipitation
FACS
EIA
Optimal working dilutions must be determined by end user.
Research Category
Cell Structure
Cell Structure
Research Sub Category
Integrins
Integrins
Physical form
Format: Purified
Storage and Stability
Maintain at 2-8°C in undiluted aliquots for up to 6 months.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Tropism-modified AAV vectors overcome barriers to successful cutaneous therapy.
Sallach, J; Di Pasquale, G; Larcher, F; Niehoff, N; Rubsam, M; Huber, A; Chiorini et al.
Molecular Therapy null
Maria Rita Milone et al.
Oncotarget, 6(7), 5324-5341 (2014-12-08)
Proteomic analysis identified differentially expressed proteins between zoledronic acid-resistant and aggressive DU145R80 prostate cancer (PCa) cells and their parental DU145 cells. Ingenuity Pathway Analysis (IPA) showed a strong relationship between the identified proteins within a network associated with cancer and
Keijiro Ishikawa et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 28(1), 131-142 (2013-09-12)
Proliferative vitreoretinopathy (PVR) is a severe, vision-threatening disorder characterized by the fibrous membrane formation that leads to tractional retinal detachment. There has been no effective therapeutic approach other than vitreoretinal surgery. In this study, DNA microarray analysis of the fibrous
Mannose 6-phosphate/insulin-like growth factor 2 receptor limits cell invasion by controlling alphaVbeta3 integrin expression and proteolytic processing of urokinase-type plasminogen activator receptor.
Schiller, HB; Szekeres, A; Binder, BR; Stockinger, H; Leksa, V
Molecular Biology of the Cell null
D H Chai et al.
Osteoarthritis and cartilage, 18(2), 249-256 (2009-10-06)
Our goal was to test the hypothesis that specific integrin receptors regulate chondrocyte biosynthetic response to dynamic compression at early times in 3D gel culture, during initial evolution of the pericellular matrix, but prior to significant accumulation of further-removed matrix.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service